WallStSmart

Apyx Medical Inc (APYX)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 47429% more annual revenue ($25.12B vs $52.84M). SYK leads profitability with a 12.9% profit margin vs -21.2%. APYX appears more attractively valued with a PEG of 0.59. SYK earns a higher WallStSmart Score of 65/100 (C+).

APYX

Hold

40

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 6.7Quality: 5.0

SYK

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for APYX.

SYKUndervalued (+16.8%)

Margin of Safety

+16.8%

Fair Value

$393.59

Current Price

$327.65

$65.94 discount

UndervaluedFair: $393.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APYX2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
34.7%10/10

Revenue surging 34.7% year-over-year

PEG RatioValuation
0.598/10

Growing faster than its price suggests

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$125.72B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

Areas to Watch

APYX4 concerns · Avg: 3.5/10
Price/BookValuation
11.1x4/10

Trading at 11.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$145.57M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.1%3/10

Operating margin of 0.1%

SYK3 concerns · Avg: 3.7/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : APYX

The strongest argument for APYX centers on Revenue Growth, PEG Ratio. Revenue growth of 34.7% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.

Bear Case : APYX

The primary concerns for APYX are Price/Book, EPS Growth, Market Cap.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

APYX profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.

APYX carries more volatility with a beta of 1.66 — expect wider price swings.

APYX is growing revenue faster at 34.7% — sustainability is the question.

SYK generates stronger free cash flow (1.9B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (65/100 vs 40/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Apyx Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?